This site is intended for US healthcare professionals
Alkermes logo
Alkermes logo
Educational Resources
Resources Home
Congresses
Product Information
Our Pipeline
Knowledge Vault
Contact an MSL
Medical Information
Research & Medical Grants

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

Neuroscience Education Institute
November 9th – 12th 2023, Colorado Springs, CO
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Rakesh Jain,1 Hemangi R. Panchmatia,2 Alejandro G. Hughes,3 Noah S. Webb,3 Michael J. Doane,2 Andrew J. Cutler4,5

View poster
Bipolar Disorder
Schizophrenia
Schizophrenia
ENCORE POSTER
Baseline Demographics and Clinical Characteristics From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia
AUTHOR(S)

Lauren N. Strand,1 Michael J. Doane,1 Christina Arevalo,1 James A. McGrory,1 Peter J. Weiden,2 Eric D. Achtyes,3 Phillip D. Harvey,4 John M. Kane,5 Stephen R. Saklad,6 Jeffrey Trotter,7 Dawn I. Velligan8

View poster
Schizophrenia
Schizophrenia
ENCORE POSTER
Treatment Patterns From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia
AUTHOR(S)

Lauren N. Strand,1 Michael J. Doane,1 Christina Arevalo,1 James A. McGrory,1 Peter J. Weiden,2 Eric D. Achtyes,3 Phillip D. Harvey,4 John M. Kane,5 Stephen R. Saklad,6 Jeffrey Trotter,7 Dawn I. Velligan8

View poster
Schizophrenia
Schizophrenia
ENCORE POSTER
Outcomes From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia
AUTHOR(S)

Lauren N. Strand,1 Michael J. Doane,1 Christina Arevalo,1 James A. McGrory,1 Peter J. Weiden,2 Eric D. Achtyes,3 Phillip D. Harvey,4 John M. Kane,5 Stephen R. Saklad,6 Jeffrey Trotter,7 Dawn I. Velligan8

View poster
Schizophrenia
Schizophrenia
ENCORE POSTER
Key Characteristics of the Atypical Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Schizophrenia
AUTHOR(S)

Leslie Citrome,1 Christoph U. Correll,2-4 Gregory W. Mattingly,5 Andrew J. Cutler,6 Amber R. Hoberg,7 Peter J. Weiden,8 Bhaskar Rege,9 James A. McGrory,9 Martin Dunbar,9 Craig Hopkinson,9 David McDonnell10

View poster
Schizophrenia
Bipolar Disorder
ENCORE POSTER
Burden of Bipolar I Disorder on Clinical, Economic, and Humanistic Outcomes: Matched Analysis of US National Health and Wellness Survey Data
AUTHOR(S)

Michael J. Doane,1 Adam Jauregui,2 Hemangi Panchmatia1

View poster
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Aripiprazole Lauroxil 2-Month Formulation for Acute Schizophrenia: A Post Hoc Analysis of PANSS Factor Scores in the ALPINE Study
AUTHOR(S)

Leslie Citrome,1 James A. McGrory,2 Martin Dunbar2

View poster
Schizophrenia
Alcohol Use Disorder
Non-specific
Opioid Use Disorder
ENCORE POSTER
Opioid Antagonists: Clinical Utility, Pharmacology, and Safety and Tolerability
AUTHOR(S)

Roger S. McIntyre,1 Marni White,2 Mark S. Todtenkopf,2 Sarah Akerman,2 Joshua Burgett3

View poster
Alcohol Use Disorder
Non-specific
Opioid Use Disorder
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Olanzapine/Samidorphan Effects on Weight Gain: A Meta-analysis of Phase 2 and 3 Randomized, Double-Blind Studies
AUTHOR(S)

Christoph Correll,1-3 Michael J. Doane,4 David McDonnell,5 Sarah Akerman,4 Stephen R. Saklad6

View poster
Bipolar Disorder
Schizophrenia
Narcolepsy
ENCORE POSTER
Diagnosis and Symptoms of Narcolepsy From the Patient Perspective: Results From In-Depth Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 and Wilbur P. Williams, III1

View poster
Narcolepsy
Contact Us Terms of Use Privacy Policy www.alkermes.com

The product information provided on this site is intended only for healthcare professionals in the United States and is for informational purposes only. This site is designed to provide background and scientific findings concerning Alkermes products and areas of therapeutic interest. Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

If you have a suspected Adverse Event or Product Complaint to report, please contact us by phone at 888-235-8008 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Your use of this information is subject to the terms and conditions of our Privacy Policy.

© 2024 Alkermes, Inc. All rights reserved. MA-004230

Please review our Privacy Policy.

By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Policy. Learn more.

Close
This site is intended for US healthcare professionals
Alkermes Logo
Educational Resources
Congresses
Product Information
Our Pipeline
Contact an MSL
Medical Information
Research & Medical Grants